|[July 04, 2014]
Research and Markets: Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/fpztpk/opportunityanalyze)
has announced the addition of the "Opportunity
Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and
Forecasts to 2018" report to their offering.
Chronic lymphocytic leukemia (CLL), the most common form of adult
leukemia, is caused by the uncontrolled proliferation of B lymphocytes
(a type of white blood cell) in the bone marrow, blood and lymphoid
tissues. This report focuses on the current treatment landscape, unmet
needs, pipeline and commercial opportunity in the CLL market with
coverage of both the first-line and relapsed/refractory settings.
While the current standard of care consists of chemoimmunotherapy, CLL
disease management is poised for dramatic changes, particularly in the
treatment of relapsed/refractory and elderly patients, as four new drugs
(Gazyva, Imbruvica, idelalisib and IPI-145) will launch during the
Key Questions Answered
Which CLL patients have the greatest unmet needs and how well will
these needs be addressed by the new agents?
How will CLL disease management change as new agents enter the market?
What are the R&D and clinical trial design strategies pursued by
companies in the CLL space?
What are the most promising late-stage pipeline agents for CLL? How do
their clinical and commercial attributes compare to one another and
the current standards of care?
What opportunities will remain for future players following the launch
of these pipeline agents?
What exciting, innovative approaches are being investigated in the
early-stage CLL pipeline?
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
6 Current Treatment Options
7 Unmet Needs Assessment and Oppportunity Analysis
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/fpztpk/opportunityanalyze
[ Back To Technology News's Homepage ]